Adaptate Biotherapeutics Appoints Stewart Kay as Chief Business Officer
Complete the form below to unlock access to ALL audio articles.
Adaptate Biotherapeutics (Adaptate), a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced the appointment of Stewart Kay as Chief Business Officer (CBO). In this new role, Stewart will work as part of the Executive team to drive Adaptate’s Business and Corporate Development activities.
Adaptate is developing a number of therapeutic antibodies that recognize drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells are a distinct T cell sub-type that respond to molecular patterns of distress in situ and have been shown to have tremendous potential in treating cancer and other immunological disorders.
Stewart joins Adaptate with over 20 years’ experience in business development in both biotech and big pharma. Most recently he was Chief Business Officer at Crescendo Biologics and prior to that was Senior Director, Transactions, at GlaxoSmithKline (GSK), in the Worldwide Business Development group. Stewart has broad experience over a wide variety of deals across multiple therapeutic areas. He has been responsible for a range of early and late-stage clinical in- and out-licensing agreements and numerous transactions relating to pre-clinical assets and technology platforms. Before joining GSK, Stewart also held senior business development roles at Asterand plc and Evotec AG. He holds a BSc (Hons) in Biochemistry and an MBA from Warwick University Business School.
Dr Natalie Mount, CEO of Adaptate Biotherapeutics, said: “We have made rapid progress at Adaptate over our first year of operations. Stewart brings a wealth of business development experience and extensive knowledge of the pharma and life sciences sector. We welcome him to the Adaptate team as we enter this next phase of development of the company and progression of our pipeline.”
Stewart Kay, CBO of Adaptate Biotherapeutics commented: “I am delighted to be joining Adaptate at such an exciting time for the company. Adaptate have established themselves as leaders in developing therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells. I have been impressed at the pace of progress achieved and look forward to working with the team to realize the potential of this next generation of immunotherapy.”
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
